Status:

COMPLETED

Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

Lead Sponsor:

Intra-Cellular Therapies, Inc.

Conditions:

Bipolar Depression

Major Depressive Disorder

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes as...

Eligibility Criteria

Inclusion

  • Major
  • Male or female subjects of any race, ages 18-75 inclusive
  • Meets the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM 5) criteria for Bipolar I or Bipolar II Disorder or MDD
  • The start of the current major depressive episode is at least 2 weeks but no more than 6 months prior to the Screening (Visit 1)
  • Has at least moderate severity of illness, as measured by a rater-administered MADRS total score ≥ 24 and corresponding to a CGI S score of ≥ 4 at Screening (Visit 1) and Baseline (Visit 2)
  • The patient meets the DSM-5 criteria for mixed-features specific to the Bipolar I or II diagnosis or MDD diagnosis
  • Current major depressive episode is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning
  • Able to provide written informed consent
  • Major

Exclusion

  • Any female subject who is pregnant or breast-feeding
  • Any subject judged to be medically inappropriate for study participation
  • The patient has a significant risk for suicidal behavior
  • The patient presents with a lifetime history of epilepsy, seizure or convulsion, or electroencephalogram with clinically significant abnormalities, delirium, dementia, amnestic, or other cognitive disorder or significant brain trauma

Key Trial Info

Start Date :

February 27 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 30 2022

Estimated Enrollment :

488 Patients enrolled

Trial Details

Trial ID

NCT04285515

Start Date

February 27 2020

End Date

November 30 2022

Last Update

March 19 2025

Active Locations (42)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (42 locations)

1

Clinical Site

Garden Grove, California, United States, 92845

2

Clinical Site

Oceanside, California, United States, 92056

3

Clinical Site

Sherman Oaks, California, United States, 91403

4

Clinical Site

Lauderhill, Florida, United States, 33319